-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On December 20th, at the third extraordinary general meeting of shareholders held in 2021, Dongyang Sunshine considered the sale of shares in its holding subsidiary Dongyang Sun Pharmaceuticals and the provision of guarantees for the wholly-owned Sun Company
.
On the same day, Dongyang Sunshine issued an announcement stating that the above-mentioned proposals have been reviewed and passed, and Dongyang Sunshine formally divested its pharmaceutical business
.
Earlier, Dongyang Sunshine issued an announcement stating that the company intends to transfer the company's total 452 million shares of Dongyang Sunshine to Guangyao and Hong Kong Dongyang Sunshine, accounting for 51.
41% of the total share capital of Dongyang Sunshine, and the transaction price is 3.
723 billion yuan
.
Before this equity transfer, Dongyang Sunshine mainly used its subsidiary Dongyang Sunshine Pharmaceutical to carry out its pharmaceutical manufacturing business.
In 2020, its pharmaceutical manufacturing business will account for nearly 23% of its revenue
.
However, due to the impact of the epidemic, Dongyang Pharmaceutical's performance will decline significantly in 2020, with revenue and net profit falling by 62.
27% and 56.
09% year-on-year, respectively
.
In the first three quarters of this year, the company's revenue was 9.
07 billion yuan, up 14.
83% year-on-year, and non-net profit was 82.
51 million yuan, down 14.
62% year-on-year
.
For Dongyang Sunshine, the equity sale obtained about 3.
7 billion yuan in cash, which can supplement the company's operating capital needs
.
The company said that after divesting its pharmaceutical business, it will focus its energy and resources on strengthening advantageous industries such as new electronic materials, and at the same time extend it to the field of new energy batteries through cooperation and self-research
.
According to the announcement previously issued by Dongyang Sunshine, the company will realize the integrated electronic new material industry chain of "electronic optical foil-electrode foil-aluminum electrolytic capacitor", air-conditioning heat exchanger industry chain, and chloro-fluorine circular economy industry chain.
On the basis of related businesses, deepen the integration of the upstream and downstream of the related industry chain
.
In the near future, in addition to Dongyang Sunshine, Yan’an Bikang also intends to divest its pharmaceutical business.
On December 11, Yan’an Bikang issued an announcement stating that in order to gradually divest its pharmaceutical business and further improve and adjust the industry and investment structure, Yan’an Bikang and Nanhua Bio-Bio signed the "Asset Purchase Intention Agreement" and intends to sell the equity of some pharmaceutical companies and pharmaceutical circulation companies under Yan'an Bikang and/or the assets corresponding to some production workshops to Nanhua Bio-Bio.
The specific scope of assets is subject to negotiation between the two parties.
.
Judging from the performance of Yan'an Bikang in recent years, the revenue growth rate from 2016 to 2018 reached 84.
04%, 44% and 57%, and the net profit was 962 million yuan, 901 million yuan and 426 million yuan, respectively.
The performance began to decline significantly
.
However, in 2021, affected by the favorable market environment of new energy product lithium hexafluorophosphate, the company achieved a net profit of 609 million yuan attributable to shareholders of listed companies in the first three quarters, a year-on-year increase of 4672.
62%
.
Regarding the asset sale, Yanan Bikang said it will help the company to grasp the development window of new energy and new materials in a timely manner, accelerate the realization of strategic layout, and enhance the ability of sustainable operation and healthy development
.
In addition to the above-mentioned cases where the two pharmaceutical companies directly divested the entire pharmaceutical sector, many pharmaceutical companies are also actively seeking to transform and sell some assets.
For example, in December, Meikang Shengda Bio, a wholly-owned subsidiary of Meikang Biologics, planned to transfer its holdings for 44,918,100 yuan.
Some Zhejiang Yongjie 51% equity; On December 6, Xiangxue Pharmaceutical transferred 100% equity of Xiangxue Biotechnology to Guangdong Minsheng Investment (Guangzhou) Financial Investment Co.
, Ltd.
through equity transfer for 18 million yuan
.
From the perspective of the above-mentioned pharmaceutical companies that have sold assets, the purpose is mostly to divest non-core businesses and concentrate their advantages on the development of their main businesses
.
It can be seen that the reform of the pharmaceutical market continues to take place
.
.
On the same day, Dongyang Sunshine issued an announcement stating that the above-mentioned proposals have been reviewed and passed, and Dongyang Sunshine formally divested its pharmaceutical business
.
Earlier, Dongyang Sunshine issued an announcement stating that the company intends to transfer the company's total 452 million shares of Dongyang Sunshine to Guangyao and Hong Kong Dongyang Sunshine, accounting for 51.
41% of the total share capital of Dongyang Sunshine, and the transaction price is 3.
723 billion yuan
.
Before this equity transfer, Dongyang Sunshine mainly used its subsidiary Dongyang Sunshine Pharmaceutical to carry out its pharmaceutical manufacturing business.
In 2020, its pharmaceutical manufacturing business will account for nearly 23% of its revenue
.
However, due to the impact of the epidemic, Dongyang Pharmaceutical's performance will decline significantly in 2020, with revenue and net profit falling by 62.
27% and 56.
09% year-on-year, respectively
.
In the first three quarters of this year, the company's revenue was 9.
07 billion yuan, up 14.
83% year-on-year, and non-net profit was 82.
51 million yuan, down 14.
62% year-on-year
.
For Dongyang Sunshine, the equity sale obtained about 3.
7 billion yuan in cash, which can supplement the company's operating capital needs
.
The company said that after divesting its pharmaceutical business, it will focus its energy and resources on strengthening advantageous industries such as new electronic materials, and at the same time extend it to the field of new energy batteries through cooperation and self-research
.
According to the announcement previously issued by Dongyang Sunshine, the company will realize the integrated electronic new material industry chain of "electronic optical foil-electrode foil-aluminum electrolytic capacitor", air-conditioning heat exchanger industry chain, and chloro-fluorine circular economy industry chain.
On the basis of related businesses, deepen the integration of the upstream and downstream of the related industry chain
.
In the near future, in addition to Dongyang Sunshine, Yan’an Bikang also intends to divest its pharmaceutical business.
On December 11, Yan’an Bikang issued an announcement stating that in order to gradually divest its pharmaceutical business and further improve and adjust the industry and investment structure, Yan’an Bikang and Nanhua Bio-Bio signed the "Asset Purchase Intention Agreement" and intends to sell the equity of some pharmaceutical companies and pharmaceutical circulation companies under Yan'an Bikang and/or the assets corresponding to some production workshops to Nanhua Bio-Bio.
The specific scope of assets is subject to negotiation between the two parties.
.
Judging from the performance of Yan'an Bikang in recent years, the revenue growth rate from 2016 to 2018 reached 84.
04%, 44% and 57%, and the net profit was 962 million yuan, 901 million yuan and 426 million yuan, respectively.
The performance began to decline significantly
.
However, in 2021, affected by the favorable market environment of new energy product lithium hexafluorophosphate, the company achieved a net profit of 609 million yuan attributable to shareholders of listed companies in the first three quarters, a year-on-year increase of 4672.
62%
.
Regarding the asset sale, Yanan Bikang said it will help the company to grasp the development window of new energy and new materials in a timely manner, accelerate the realization of strategic layout, and enhance the ability of sustainable operation and healthy development
.
In addition to the above-mentioned cases where the two pharmaceutical companies directly divested the entire pharmaceutical sector, many pharmaceutical companies are also actively seeking to transform and sell some assets.
For example, in December, Meikang Shengda Bio, a wholly-owned subsidiary of Meikang Biologics, planned to transfer its holdings for 44,918,100 yuan.
Some Zhejiang Yongjie 51% equity; On December 6, Xiangxue Pharmaceutical transferred 100% equity of Xiangxue Biotechnology to Guangdong Minsheng Investment (Guangzhou) Financial Investment Co.
, Ltd.
through equity transfer for 18 million yuan
.
From the perspective of the above-mentioned pharmaceutical companies that have sold assets, the purpose is mostly to divest non-core businesses and concentrate their advantages on the development of their main businesses
.
It can be seen that the reform of the pharmaceutical market continues to take place
.
